Collaborator within Phraktion network, consultant for Pharma, supporting: Development of Publication Policies, SOPs, Working InstructionsManuscript review / editingTraining Materials and Mentoring

Website: http://tinyurl.com/kbpscicommsllcDEVELOPMENT OF DOCUMENTATION TO SUPPORT SCIENTIFIC COMMUNICATIONS DEPARTMENTS:Publication policiesStandard operating proceduresReference documentsWorking instructionsPlaybooksFAQsMANUSCRIPT REVIEW:Manuscript editing (abstracts, manuscripts, posters)Review and edit publications to ensure adherence to Good Publication PracticeData qc for abstract and manuscript draftsTRAINING AND MENTORINGAssistance for the training of staff new to Scientific Communications on Good Publication PracticeAssistance with the development of strategic and tactical communication plans

Provided consultancy support on topics related to Publication Policies and implementation of publications best practices.Supported the hiring, onboarding, and mentorship of new FTEs in support of the Meta+ Franchise.Provide editorial support for scientific publications in support of the Wilson’s Disease Therapeutic Area.

Led creation and execution of global scientific communications strategy and publication plans for eculizumab (PNH, aHUS, DGF), ravulizumab (PNH and COVID-19), and danicopan (geographic atrophy) in accordance with the existing global strategies. Ensure alignment across Global, Regional and Local publication plans. Drove timely execution of publication plans to produce high quality, accurate and impactful deliverables. Planned, developed and implemented educational plans that communicated important information to the medical and scientific community. Established strong collaborative relationships and worked in close partnership with other members of Global Medical Affairs and key internal and external stakeholders.

Led publication group within the Department of Clinical Development/Medical Affairs, comprised of 5 Direct Reports and 4 Indirect Reports. Provided leadership, in addition to strategic and tactical direction for the Medical Publication function across Clinical Development and Medical Affairs. Reviewed and provided input into the development and execution of Therapeutic Area Medical Affairs Plans from a functional perspective to achieve key medical/scientific objectives and provide support for the identification and development of high-quality medical publications. Collaborated across US and Global entities to build close working relationships with domestic and Corporate Clinical Development and Medical Affairs and Scientific Affairs colleagues as a basis of ensuring strategic alignment of global and functional and organizational strategies and local and global publication objectives. Built key strategic relationships with external stakeholders to collect information about publication best practices, emerging trends, the regulatory environment, journal or publishing requirements/changes and research needs to facilitate best practice in medical publications in the company. Provided expertise, guidance, and support to other Clinical Development and Medical Affairs colleagues. Participated in Therapeutic Area Steering Committees as a Functional Leader.

In the "Medical Communications Quality & Practices" Department, under the Office of the CMO, supported and implemented Scientific Engagement vision by1. providing a long-term centre of excellence to embed Scientific Engagement Practices across GSK for Publications and Congress Data Presentations.2. providing operational support to implement these Scientific Engagement Practices for biopharmaceutical assets in the therapeutic areas encompassing type 2 diabetes, oncology, rheumatoid arthritis, and multiple sclerosis. 3. developing, maintaining and executing Data Dissemination Plans, and ancillary activities (i.e., publication steering committees).

Led development and execution of all Scientific Communications activities associated with the incretin portfolio for type 2 diabetes. Collaborated with multidisciplinary team to foster scientific exchange and communicate GSK science in a transparent, credible and timely way to inform good medical practice and optimize patient outcomes. Programs included scientific publications and presentations, external expert engagement, advisory boards, symposia and medical education. Budget accountability: $900,000/year.

Led Global and Regional cross-functional Publication Core Teams to design and implement publications and related Scientific Affairs activities to support various assets in the cardiovascular, metabolic, urologic and hematologic therapeutic areas. Led the Phase IV Protocol Review Committee to review and assess investigator-initiated studies to support the hematology biologicals franchise.

Solely responsible for the development and execution of my research program (extramural funding, identification of resources and environment, technical budget, experimental and analytical methods, experimental design and statistics, and manuscript development and publication). Results of research published in 16 primary manuscripts (6 as first author) and 10 peer-reviewed review articles. Presented this research at scientific meetings as abstract presentations and plenary talks. As faculty member, was also responsible for the training and supervision of technicians, post-doctoral fellows, and pre-doctoral trainees.

Overall research goal was to gain an understanding of the beneficial / detrimental effects of plasma lipoproteins on cells comprising the vascular wall. Results of my work were published in 3 first-author peer-reviewed manuscripts.

Computer-aided analysis of 24-hour Holter ECGs for experimental protocols.

Bone Mineral Density in Renal Osteodystrophy: data acquisition, analysis, summary reports.